Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma
Sponsor: Guangxi Medical University
Summary
Though hepatectomy is one of the curative treatment for patients with hepatocellular carcinoma (HCC), the 5-years recurrence-free survival is lower than 30%. In recent years, several immune checkpoint inhibitors have been approved in advanced HCC. However, no study about the safety and efficacy of adjuvant immune checkpoint inhibitors for patients with HCC after hepatectomy was reported.
Official title: Adjuvant Immune CheckPoint InhibitoRs Based ThErapy in PostoperatiVe HEpatocellular CarciNoma: a ProspecTive Real-world Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
10000
Start Date
2019-03-03
Completion Date
2030-12-30
Last Updated
2026-10-07
Healthy Volunteers
No
Conditions
Interventions
Immune Checkpoint Inhibitors Based Adjuvant therapy
Patients in this group will recieve immune checkpoint inhibitors based adjuvant therapy
Active surveillance
Patients in this group only receive active surveillance
Locations (1)
Jian-Hong Zhong
Nanning, Guangxi, China